Wedbush Upgrades Zentalis Pharmaceuticals to Outperform, Raises Price Target to $6

Benzinga · 2d ago
Wedbush analyst Robert Driscoll upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) from Neutral to Outperform and raises the price target from $5 to $6.